Tag Archives: Thioridazine

Pharmacological Treatment of Dementia

General guidelines for psychotropic medication use in frail elderly patients are applicable. Systematic evidence to support the effectiveness of particular psychotropic drugs in dementia patients is limited. Therefore, choice of drug class may be based on clinical evidence, and choice of agent is often based on the side-effect profile and on the characteristics of a… Read More »

Information about Alzheimer’s Disease for Patients and Families

Alzheimer’s disease is the most common and well-known form of degenerative dementia. By definition, dementia is a syndrome, a cluster of symptoms, of impaired memory and cognition. Dementia is a cognitive disorder that impairs an individual’s memory and ability for reasoning, awareness, and judgment. Cognitive impairment in Alzheimer’s disease may involve disturbance of language (aphasia),… Read More »

Pharmacotherapy in the Treatment of People With Schizophrenia

The pharmacological agents most primarily associated with treatment of schizophrenia are grouped in a large and heterogeneous family, the antipsychotics. Recently, this family has been subdivided into the typicals, or neuroleptics, and the atypicals (see Tables Selected Typical Antipsychotic Drugs and Their Characteristics and Atypical Antipsychotics: Relative Potencies and Side Effects). The neuroleptics are so… Read More »

Adjunctive Pharmacotherapy and Related Issues

Managing antipsychotic side effects. Antipsychotic drugs produce problematic side effects in many individuals (see Table Side Effects of Typical Antipsychotic Drugs). A major category of side effects results from neurotransmitter dysregulation of the extra-pyramidal motor system. It is thought that these side effects are the result of an imbalance of dopaminergic and acetylcholinergic activity in… Read More »

Chronic Illness: Current Therapies

The main goal of bipolar disorder drug treatment is to establish euthymia (stable mood with a persistent sense of well-being) without inducing mania or rapid cycling (i.e., four or more mood episodes in a 12-month period). For this reason, drug treatment usually consists of an agent or, more frequently, combinations of agents that exert both… Read More »

Pharmacological treatment for schizophrenia

Pharmacological treatments are an essential component of a comprehensive approach to the treatment of schizophrenia. Rational pharmacotherapies can contribute greatly to symptom relief and to a broader psychosocial recovery for affected individuals. However, antipsychotic drugs do not cure schizophrenia. Moreover, if not used judiciously, drug therapies can create significant financial, side-effect, and medical morbidity burdens… Read More »

Treatment for Schizophrenia: Antipsychotic Drugs

Modern drug treatment for schizophrenia dates to the early 1950s, when Deniker and Delay reported the antipsychotic effects of chlorpromazine (). Chlorpromazine was introduced in the United States in 1954, followed over the next three decades by several drugs, including fluphenazine, haloperidol, perphenazine, and thioridazine, with similar therapeutic effects. All of these so-called first-generation antipsychotics… Read More »

Common Side Effects: Monitoring and Management Recommendations

Extrapyramidal Side Effects Antipsychotic-induced EPS may occur acutely or after long-term treatment. First-generation antipsychotics, in particular high-potency neuroleptics, are more likely than second-generation antipsychotics to cause EPS when the drugs are used at usual therapeutic doses. However, as can be noted in Table Selected side effects of commonly used antipsychotic medications, considerable variation in the… Read More »

Neuroleptic treatment of schizophrenia in the elderly

Neuroleptics are commonly used to treat schizophrenia and also exogenic psychosis in elderly patients (). However, there are extremely few methodologically sound controlled trials of neuroleptic drugs in this population, especially of functional psychosis (). Clinical experience and case reports indicate that the efficacy proven in younger schizophrenic patients may be extrapolated to elderly psychotic… Read More »

Fluvoxamine: History of Use in OCD

Fluvoxamine was originally developed in Europe as an antidepressant. In most published double-blind trials in patients with depression, fluvoxamine has been shown to be significantly better than placebo and to be equal in efficacy to both TCAs and other SSRIs. Studies were also conducted with fluvoxamine in patients with obsessive-compulsive disorder on the basis of… Read More »